User login
Key clinical point: Fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus anti-vascular endothelial growth factor (VEGF) therapy (triplet group) showed no survival benefits over fluoropyrimidine and oxaliplatin/irinotecan plus anti-VEGF therapy (doublet group) in a real-world cohort of patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Major finding: Progression-free survival (hazard ratio [HR] 0.82; P = .22) and overall survival (HR 0.88; P = .48) were not significantly different between the triplet and doublet chemotherapy groups. Grade 3 or 4 adverse events were more frequent in the triplet vs doublet group (65% vs 47%).
Study details: Findings are from WJOG13219G, a retrospective study, including patients with BRAFV600E-mutant mCRC who received first-line triplet (n = 79) or doublet (n = 91) chemotherapy.
Disclosures: This study did not receive any funding. Some authors declared receiving honoraria, research funding, or consulting fees from various sources.
Source: Shimozaki K et al. WJOG13219G: The efficacy and safety of FOLFOXIRI or doublet plus anti-VEGF therapy in previously untreated BRAFV600E mutant metastatic colorectal cancer: A multi-institutional registry-based study (BRACELET study). Clin Colorectal Cancer. 2022 (Aug 11). Doi: 10.1016/j.clcc.2022.08.002
Key clinical point: Fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus anti-vascular endothelial growth factor (VEGF) therapy (triplet group) showed no survival benefits over fluoropyrimidine and oxaliplatin/irinotecan plus anti-VEGF therapy (doublet group) in a real-world cohort of patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Major finding: Progression-free survival (hazard ratio [HR] 0.82; P = .22) and overall survival (HR 0.88; P = .48) were not significantly different between the triplet and doublet chemotherapy groups. Grade 3 or 4 adverse events were more frequent in the triplet vs doublet group (65% vs 47%).
Study details: Findings are from WJOG13219G, a retrospective study, including patients with BRAFV600E-mutant mCRC who received first-line triplet (n = 79) or doublet (n = 91) chemotherapy.
Disclosures: This study did not receive any funding. Some authors declared receiving honoraria, research funding, or consulting fees from various sources.
Source: Shimozaki K et al. WJOG13219G: The efficacy and safety of FOLFOXIRI or doublet plus anti-VEGF therapy in previously untreated BRAFV600E mutant metastatic colorectal cancer: A multi-institutional registry-based study (BRACELET study). Clin Colorectal Cancer. 2022 (Aug 11). Doi: 10.1016/j.clcc.2022.08.002
Key clinical point: Fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus anti-vascular endothelial growth factor (VEGF) therapy (triplet group) showed no survival benefits over fluoropyrimidine and oxaliplatin/irinotecan plus anti-VEGF therapy (doublet group) in a real-world cohort of patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer (mCRC).
Major finding: Progression-free survival (hazard ratio [HR] 0.82; P = .22) and overall survival (HR 0.88; P = .48) were not significantly different between the triplet and doublet chemotherapy groups. Grade 3 or 4 adverse events were more frequent in the triplet vs doublet group (65% vs 47%).
Study details: Findings are from WJOG13219G, a retrospective study, including patients with BRAFV600E-mutant mCRC who received first-line triplet (n = 79) or doublet (n = 91) chemotherapy.
Disclosures: This study did not receive any funding. Some authors declared receiving honoraria, research funding, or consulting fees from various sources.
Source: Shimozaki K et al. WJOG13219G: The efficacy and safety of FOLFOXIRI or doublet plus anti-VEGF therapy in previously untreated BRAFV600E mutant metastatic colorectal cancer: A multi-institutional registry-based study (BRACELET study). Clin Colorectal Cancer. 2022 (Aug 11). Doi: 10.1016/j.clcc.2022.08.002